Your healthcare provider can assess your needs and help you choose the option that aligns with your specific goals
Glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1 RA) Semaglutide and Tirzepatide, dual GIP/GLP-1 receptor agonists, have shown significant efficacy in reducing body weight and improving glucose control (Jastreboff et al
Injection Technique and Consistency The medication is typically injected subcutaneously (into the fat layer) in the abdomen, thigh, or upper arm
When taken with semaglutide, they can also raise the risk of hypoglycemia
451 While EpCAM expression is frequently associated with tumor-initiating capacity, its functional role in CSC maintenance remains controversial
For more detail on side effect patterns, our GLP-1 side effects guide can help you understand what many patients notice early on